gastro-jРоссийский журнал гастроэнтерологии, гепатологии, колопроктологииRussian Journal of Gastroenterology, Hepatology, Coloproctology1382-43762658-6673«Gastro» LLCgastro-j-1635Research ArticleЛЕКЦИИ И ОБЗОРЫLECTURES AND REVIEWSЛечение и профилактика гастропатий, индуцированных нестероидными противовоспалительными средствами, в практике терапевтаTreatment and prophylaxis of NSAID-induced gastropathies in a therapeutist’s practiceЛапинаТ. Л.LapinaT. L.2009050820091941318Copyright © Лапина Т.Л., 20092009Лапина Т.Л.Lapina T.L.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.gastro-j.ru/jour/article/view/1635

Цель обзора – представить современные данные о применении ингибиторов протонной помпы (ИПП) на примере эзомепразола для лечения и профилактики гастропатий, индуцированных приемом нестероидных противовоспалительных средств (НПВС).Основные положения. ИПП служат средствами для лечения и профилактики гастропатий, индуцированных НПВС. Недавно проведенные контролируемые исследования показали клиническую эффективность эзомепразола в ведении больных с НПВС­гастропатиями. Препарат в дозе 20 и 40 мг достоверно быстрее и у большего числа больных привел к заживлению язвы желудка по сравнению с ранитидином в дозе 300 мг за 8 нед лечения. Эзомепразол (20 и 40 мг) оказался эффективным для профилактики эрозий и язв при постоянном приеме НПВС и/или аспирина в плацебо­контролируемых исследованиях. Диспепсия, не связанная с эрозивно­язвенными поражениями верхних отделов желудочно­кишечного тракта (ЖКТ), успешно купирована назначением эзомепразола в той же дозе на 4-­й неделе лечения, а поддерживающий курс в течение 6 мес способствовал предупреждению болей и дискомфорта в эпигастральной области на фоне продолжающегося приема НПВС.Заключение. Эзомепразол может быть использован при всем спектре нежелательного влияния НПВС и аспирина на верхние отделы ЖКТ в качестве и лечебного, и профилактического средства.

The aim of review – to present up-to-date data on application of proton pump inhibitors (PPI) e.g. esomeprazole for treatment and prophylaxes of gastropathies, induced by intake of nonsteroid anti-inflammatory drugs (NSAIDs).

Original positions

Original positions. PPI serve as drugs for treatment and prophylaxis of NSAIDs-induced gastropathies. Recently carried out controlled studies showed clinical efficacy of esomeprazole in conducting patients with NSAID -gastropathies. The drug in a dose of 20 and 40 mg is significantly faster and resulted in healing of stomach ulcer at higher number of patients in comparison to ranitidine in a dose of 300 mg for 8 wks of treatment. Esomeprazole (20 and 40 mg) appeared effective for prophylaxis of erosions and ulcers at long-term intake of NSAID and-or aspirin in placebo- controlled investigations. Dyspepsia which was not related to erosiveulcerative lesions of upper regions of gastro-intestinal tract (GIT), was successfully stopped by prescription of esomeprazole in the same dose to the 4-th week of treatment, and the maintaining course for 6 months promoted the relapse of pain and epigastric discomfort on a background of ongoing intake of NSAID.

Conclusion

Conclusion. Esomeprazole can be utilized at whole spectrum of undesirable effects of NSAID and aspirin on the upper regions of GIT both for treatment and prevention.

гастропатияНПВСаспиринингибиторы протонной помпыэзомепразолgastropathyNSAIDaspirinproton pump inhibitorsesomeprazoleReferencesКаратеев А.Е., Коновалова Н.Н., Литовченко А.А. и др. // Клин. мед. – 2005. – Т. 83, – № 5. – С. 33–38.Каратеев А.Е., Коновалова Н.Н., Литовченко А.А. и др. // Клин. мед. – 2005. – Т. 83, – № 5. – С. 33–38.Каратеев А.Е., Насонова В.А. Распространенность, структура и факторы риска развития гастропатий, индуцированных НПВП // Рос. журн. гастроэнтерол. гепатол. колопроктол. – 2000. – Т. 10, № 4. – С. 34–39.Каратеев А.Е., Насонова В.А. Распространенность, структура и факторы риска развития гастропатий, индуцированных НПВП // Рос. журн. гастроэнтерол. гепатол. колопроктол. – 2000. – Т. 10, № 4. – С. 34–39.Ярустовский М.Б. и др. Эффективность применения антисекреторных препаратов в лечении острых эрозивно-язвенных повреждений у больных с приобретенными заболеваниями сердца // Рос. журн. гастроэнтерол. гепатол. колопроктол. – 2004. – Т. 14, № 6. – С. 33–39.Ярустовский М.Б. и др. Эффективность применения антисекреторных препаратов в лечении острых эрозивно-язвенных повреждений у больных с приобретенными заболеваниями сердца // Рос. журн. гастроэнтерол. гепатол. колопроктол. – 2004. – Т. 14, № 6. – С. 33–39.Abelo A., Andersson T.B., Bredberg E. et al. Stereoselective metabolism by human liver CYP enzymes of a substituted benzimidazole // Drug Metab. Dispos. – 2000. – Vol. 28. – P. 58–64.Abelo A., Andersson T.B., Bredberg E. et al. Stereoselective metabolism by human liver CYP enzymes of a substituted benzimidazole // Drug Metab. Dispos. – 2000. – Vol. 28. – P. 58–64.Ford A.C., Forman D., Bailey A.G. et al. Initial poor quality of life and new onset of dyspepsia: results from a longitudinal 10-year follow-up study // Gut. – 2007. – Vol. 56, N 3. – P. 321–327.Ford A.C., Forman D., Bailey A.G. et al. Initial poor quality of life and new onset of dyspepsia: results from a longitudinal 10-year follow-up study // Gut. – 2007. – Vol. 56, N 3. – P. 321–327.Goldstein J.L., Johanson J.F., Suchower L.J., Brown K.A. Healing of gastric ulcers with esomeprazole versus ranitidine in patients who continued to receive NSAID therapy: a randomized trial // Am. J. Gastroenterol. – 2005. – Vol. 100, N 12. – P. 2650–2657.Goldstein J.L., Johanson J.F., Suchower L.J., Brown K.A. Healing of gastric ulcers with esomeprazole versus ranitidine in patients who continued to receive NSAID therapy: a randomized trial // Am. J. Gastroenterol. – 2005. – Vol. 100, N 12. – P. 2650–2657.Hawkey C.J., Jones R.H., Yeomans N.D. et al. Efficacy of esomeprazole for resolution of symptoms of heartburn and acid regurgitation in continuous users of non-steroidal anti-inflammatory drugs // Aliment. Pharmacol. Ther. – 2007. – Vol. 25, N 7. – P. 813–821.Hawkey C.J., Jones R.H., Yeomans N.D. et al. Efficacy of esomeprazole for resolution of symptoms of heartburn and acid regurgitation in continuous users of non-steroidal anti-inflammatory drugs // Aliment. Pharmacol. Ther. – 2007. – Vol. 25, N 7. – P. 813–821.Hawkey C.J., Karrasch J.A., Szczepanski L. et al. Omeprazole compared with misoprostole for ulcers associated with non-steroidal anti-inflammatory drugs // N. Engl. J. Med. – 1998. – Vol. 338. – P. 727–734.Hawkey C.J., Karrasch J.A., Szczepanski L. et al. Omeprazole compared with misoprostole for ulcers associated with non-steroidal anti-inflammatory drugs // N. Engl. J. Med. – 1998. – Vol. 338. – P. 727–734.Hawkey C.J., Lanas A.I. Doubt and certainty about non-steroidal anti-inflammatory drugs in the year 2000: a multidisciplinary expert statement // Am. J. Med. – 2001. – Vol. 110. – P. 79–100.Hawkey C.J., Lanas A.I. Doubt and certainty about non-steroidal anti-inflammatory drugs in the year 2000: a multidisciplinary expert statement // Am. J. Med. – 2001. – Vol. 110. – P. 79–100.Hawkey C.J., Talley N.J., Scheiman J.M. et al. Maintenance treatment with esomeprazole following initial relief of non-steroidal anti-inflammatory drug-associated upper gastrointestinal symptoms: the NASA2 and SPACE2 studies // Arthritis Res. Ther. – 2007. – Vol. 9, N 1. – P. 17.Hawkey C.J., Talley N.J., Scheiman J.M. et al. Maintenance treatment with esomeprazole following initial relief of non-steroidal anti-inflammatory drug-associated upper gastrointestinal symptoms: the NASA2 and SPACE2 studies // Arthritis Res. Ther. – 2007. – Vol. 9, N 1. – P. 17.Hawkey C.J., Talley N.J., Yeomans N.D. et al. Improvements with esomeprazole in patients with upper gastrointestinal symptoms taking non-steroidal anti-inflammatory drugs, including selective COX-2 inhibitors // Am. J. Gastroenterol. – 2005. – Vol. 100, N 5. – P. 1028–1036.Hawkey C.J., Talley N.J., Yeomans N.D. et al. Improvements with esomeprazole in patients with upper gastrointestinal symptoms taking non-steroidal anti-inflammatory drugs, including selective COX-2 inhibitors // Am. J. Gastroenterol. – 2005. – Vol. 100, N 5. – P. 1028–1036.Malfertheiner P., Megraud F., O`Morain C. et al. Current concept in the management of Helicobacter pylori infection: the Maastricht III Consensus Report // Gut. – 2007. – Vol. 56. – P. 772–781.Malfertheiner P., Megraud F., O`Morain C. et al. Current concept in the management of Helicobacter pylori infection: the Maastricht III Consensus Report // Gut. – 2007. – Vol. 56. – P. 772–781.Ofman J.J., Maclean C.H., Straus W.L. et al. Meta-analysis of dyspepsia and non-steroidal anti-inflammatory drugs // Arthritis Rheum. – 2003. – Vol. 49, N 4. – P. 508–518.Ofman J.J., Maclean C.H., Straus W.L. et al. Meta-analysis of dyspepsia and non-steroidal anti-inflammatory drugs // Arthritis Rheum. – 2003. – Vol. 49, N 4. – P. 508–518.Scheiman J.M., Yeomans N.D., Talley N.J. et al. Prevention of ulcers by esomeprazole in at-risk patients using non-selective NSAIDs and COX-2 inhibitors // Am. J. Gastroenterol. – 2006. – Vol. 101. – P. 701–710.Scheiman J.M., Yeomans N.D., Talley N.J. et al. Prevention of ulcers by esomeprazole in at-risk patients using non-selective NSAIDs and COX-2 inhibitors // Am. J. Gastroenterol. – 2006. – Vol. 101. – P. 701–710.Wildner-Christensen M., Hansen J.M., De Muckadell O.B. Risk factors for dyspepsia in a general population: non-steroidal anti-inflammatory drugs, cigarette smoking and unemployment are more important than Helicobacter pylori infection // Scand. J. Gastroenterol. – 2006. – Vol. 41, N 2. – P. 149–154.Wildner-Christensen M., Hansen J.M., De Muckadell O.B. Risk factors for dyspepsia in a general population: non-steroidal anti-inflammatory drugs, cigarette smoking and unemployment are more important than Helicobacter pylori infection // Scand. J. Gastroenterol. – 2006. – Vol. 41, N 2. – P. 149–154.Yeomans N., Lanas A., Labenz J. et al. Efficacy of esomeprazole (20 mg once daily) for reducing the risk of gastroduodenal ulcers associated with continuous use of low-dose aspirin // Am. J. Gastroenterol. – 2008. – Vol. 103, N 10. – P. 2465–2473.Yeomans N., Lanas A., Labenz J. et al. Efficacy of esomeprazole (20 mg once daily) for reducing the risk of gastroduodenal ulcers associated with continuous use of low-dose aspirin // Am. J. Gastroenterol. – 2008. – Vol. 103, N 10. – P. 2465–2473.Yeomans N.D., Tulassay Z., Juhasz L. et al. A comparison of omeprazole with ranitidine for ulcers associated with non-steroidal anti-inflammatory drugs // N. Engl. J. Med. – 1998. – Vol. 338. – P. 719–726.Yeomans N.D., Tulassay Z., Juhasz L. et al. A comparison of omeprazole with ranitidine for ulcers associated with non-steroidal anti-inflammatory drugs // N. Engl. J. Med. – 1998. – Vol. 338. – P. 719–726.

The authors declare that there are no conflicts of interest present.